Human intestinal microbiota: characterization of a simplified and stable gnotobiotic rat model.
2011Gut microbes
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Discovery of the gut microbial signature driving the efficacy of prebiotic intervention in obese patients.
2020Gut
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Probiotic-enriched milk and dairy products increase gut microbiota diversity: a comparative study.
2020Nutrition research (New York, N.Y.)
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Specific gut microbial, biological, and psychiatric profiling related to binge eating disorders: A cross-sectional study in obese patients.
2021Clinical nutrition (Edinburgh, Scotland)
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Gut Microbiota of Chinese Obese Children and Adolescents With and Without Insulin Resistance.
2021Frontiers in endocrinology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
A predictive regression model of the obesity-related inflammatory status based on gut microbiota composition.
2021International journal of obesity (2005)
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Associations between Maternal Diet, Body Composition and Gut Microbial Ecology in Pregnancy.
2021Nutrients
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Average gut flora in healthy Japanese subjects stratified by age and body mass index.
2022Bioscience of microbiota, food and health
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
The Effect of Short-Term Consumption of Lactic Acid Bacteria on the Gut Microbiota in Obese People.
2022Nutrients
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
The Intestinal Microbiota and Short-Chain Fatty Acids in Association with Advanced Metrics of Glycemia and Adiposity Among Young Adults with Type 1 Diabetes and Overweight or Obesity.
2022Current developments in nutrition
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
d-Arabitol Ameliorates Obesity and Metabolic Disorders via the Gut Microbiota-SCFAs-WAT Browning Axis.
2023Journal of agricultural and food chemistry
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Associations of disordered eating with the intestinal microbiota and short-chain fatty acids among young adults with type 1 diabetes.
2023Nutrition, metabolism, and cardiovascular diseases : NMCD
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Compliance with Nutritional Recommendations and Gut Microbiota Profile in Galician Overweight/Obese and Normal-Weight Individuals.
2023Nutrients
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Long-Term Changes to the Microbiome, Blood Lipid Profiles and IL-6 in Female and Male Swedish Patients in Response to Bariatric Roux-en-Y Gastric Bypass.
2024Nutrients
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Gut microbiome signatures associated with type 2 diabetes in obesity in Mongolia.
2024Frontiers in microbiology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Alterations in the gut microbiota community are associated with childhood obesity and precocious puberty.
2024BMC microbiology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Effect of dark sweet cherry (Prunus avium) supplementation on the fecal microbiota, metabolic endotoxemia, and intestinal permeability in obese subjects: a single-blind randomized trial.
2024Food & function
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Effect of oral metformin on gut microbiota characteristics and metabolite fractions in normal-weight type 2 diabetic mellitus patients.
2024Frontiers in endocrinology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Association analysis of gut microbiota with LDL-C metabolism and microbial pathogenicity in colorectal cancer patients.
2024Lipids in health and disease
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Faecal microbiota composition and impulsivity in a cohort of older adults with metabolic syndrome.
2024Scientific reports
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Multi-omics analyses of the gut microbiota and metabolites in children with metabolic dysfunction-associated steatotic liver disease.
2025mSystems
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Association of gut microbiota with overweight/obesity combined with gestational diabetes mellitus.
2025Journal of medical microbiology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Bacteroides- and Prevotella-enriched gut microbial clusters associate with metabolic risks.
2025Gut pathogens
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Distinct gut microbiota profiles and network properties in older Korean individuals with subjective cognitive decline, mild cognitive impairment, and Alzheimer's disease.
2025Alzheimer's research & therapy
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Changes in microbiota associated with the use of intragastric balloons.
2025Scientific reports
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
The association between gut microbiome and hypertension varies according to enterotypes: a Korean study.
2023Frontiers in microbiomes
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.